Analysis Evaluates Moore Criteria for Bevacizumab Effectiveness in Cervical Cancer

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

An analysis of a previously published phase III study prospectively validated five prognostic factors, referred to as the Moore criteria, used to identify a subset of patients with advanced cervical cancer that may not benefit from bevacizumab treatment.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe

YOU MAY BE INTERESTED IN

Throughout my career as a physician and scientist, I’ve seen ideas once considered impossible become breakthroughs that save lives. They happened because talented scientists had the resources, institutions, and sustained support to pursue ambitious ideas. Most importantly, they knew patients could not afford to wait. 

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login